Nov 16, 2004 · Relapsed AML after allogeneic SCT has a poor prognosis. So far, no standard therapy could be defined. Donor lymphocyte transfusion (DLT) has ...
We retrospectively evaluated overall survival (OS) of 489 adults with de novo AML in hematological relapse after SCT, receiving DLT (n=190) or not (n=299). ... 5 ...
Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1 year, 2 years, and 5 ...
Missing: comparison 489
Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Donor lymphocyte infusions (DLI), likewise a second allo-HCT, have become a standard approach to treat AML and MDS relapses post allo-HCT.
People also ask
What are the odds of AML coming back after bone marrow transplant?
What are the odds of relapse after stem cell transplant?
What happens if leukemia comes back after stem cell transplant?
Can DLI cure AML?
Jan 5, 2023 · The risk of relapse was reduced (6% vs 63%) and 3-year overall survival (OS) improved (80% vs 26%) compared with no intervention.20 Of note, ...
The aim of this study was to retrospectively identify the factors affecting the efficacy of DLI for adult patients with a first hematological relapse after ...
Missing: 489 | Show results with:489
Jul 25, 2023 · Donor lymphocyte infusions (DLI) have been widely employed as a method to reduce relapse probability [5]. Whereas therapeutic DLI (tDLI) are ...
Dec 22, 2014 · Complete and partial remission rates were 27% and 6%, respectively, resulting in an overall response rate of 33%. Multivariate analysis ...
Missing: transfusion 489
Mar 25, 2024 · Herein, we detail contemporary blood transfusion and transfusion medicine practices for patients undergoing HSCT.